The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: A randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis

Health Technology Assessment

Volumn 19, Issue 12, 2015, Pages 1-187

  Ball, Susan ^a   Vickery, Jane ^a   Hobart, Jeremy ^a   Wright, Dave ^a   Green, Colin ^b   Shearer, James ^b,c   Nunn, Andrew ^d   Cano, Mayam Gomez ^a   MacManus, David ^e   Miller, David ^e   Mallik, Shahrukh ^e   Zajicek, John ^a  

^a PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

^b UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRONABINOL; PLACEBO;

ARTHROPATHY; ARTICLE; BALANCE DISORDER; CONSTIPATION; COORDINATION DISORDER; DEPRESSION; DIARRHEA; DISEASE COURSE; DISSOCIATIVE DISORDER; DIZZINESS; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG USE; ECONOMIC EVALUATION; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FECES INCONTINENCE; HEALTH CARE COST; HUMAN; INFECTION; INJURY; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; MUSCLE RIGIDITY; MUSCLE SPASM; MUSCLE WEAKNESS; MUSCULOSKELETAL PAIN; NATIONAL HEALTH SERVICE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PARALLEL DESIGN; PERCEPTION DISORDER; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPASTICITY; THOUGHT DISORDER; TREMOR; URINARY TRACT INFECTION; ADULT; CLASSIFICATION; CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOUBLE BLIND PROCEDURE; ECONOMICS; FEMALE; FINANCIAL MANAGEMENT; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; NEUROIMAGING; ORAL DRUG ADMINISTRATION; PROCEDURES; PROPORTIONAL HAZARDS MODEL; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TIME; UNITED KINGDOM;

ADMINISTRATION, ORAL; ADULT; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRONABINOL; FEMALE; FINANCING, GOVERNMENT; FINANCING, PERSONAL; GREAT BRITAIN; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MUSCLE SPASTICITY; NEUROIMAGING; OUTCOME ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84923138341     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta19120     Document Type: Article

References (27)

1. Zajicek J, Ball S, Wright D, Vickery J, Nunn A, Miller D, et al. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol 2013;51:857-65. http://dx.doi.org/10.1016/S1474-4422(13)70159-5.
2. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, on behalf of the UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003;362:1517-26. http://dx.doi. org/10.1016/S0140-6736(03)14738-1.
3. Zajicek J, Fox P, Teare L. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12-months follow up. J Neurol Neurosurg Psychiatry 2005;76:1664-9. http://dx.doi.org/ 10.1136/jnnp.2005.070136.
4. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7. http://dx.doi.org/10.1002/ana.1032.
5. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomised controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001;56:1496-504. http://dx.doi.org/10.1212/WNL.56.11.1496.
6. Hobart J, Cano S. Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods. Health Technol Assess 2009;13(12)..
7. Pinheiro JC, Bates DM. Mixed-Effects Models in S and S-PLUS. New York, NY: Springer Verlag; 2000. http://dx.doi.org/10.1007/978-1-4419-0318-1.
8. Fischer JS, Jak AJ, Kniker JE, Rudick RA, Cutter GR. Multiple Sclerosis Functional Composite (MSFC) Administration and Scoring Manual. New York, NY: National Multiple Sclerosis Society; 2001..
9. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Jak AJ, et al. Use of the Multiple Sclerosis Functional Composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 2001;58:961-7. http://dx.doi.org/10.1001/archneur.58.6.961.
10. Molt RW, McAuley E, Mullen S. Longitudinal measurement invariance of the Multiple Sclerosis Walking Scale-12. J Neurol Sci 2011;305:75-9. http://dx.doi.org/10.1016/j.jns.2011.03.008.
11. Ware JE. SF-36 health survey update. Spine 2000;25:3130-9. http://dx.doi.org/10.1097/ 00007632-200012150-00008.
12. Hobart JC, Riazi A, Thompson AJ, Styles IM, Ingram W, Vickery PJ, et al. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain 2006;129:224-34. http://dx.doi.org/10.1093/brain/awh675.
13. Smith SM, De Stefano N, Jenkinson M, Matthews PM. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 2001;25:466-75. http://dx.doi.org/10.1097/ 00004728-200105000-00022.
14. Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, et al. Accurate, robust and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479-89. http://dx.doi.org/10.1006/nimg.2002.1040.
15. Andrich D. A rating formulation for ordered response categories. Psychometrika 1978;43:561-73. http://dx.doi.org/10.1007/BF02293814.
16. Andrich D. Rasch Models for Measurement. Beverley Hills, CA: Sage Publications; 1988..
17. Hobart J, Cano S, Zajicek J, Thompson AJ. Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol 2007;6:1094-105. http://dx.doi.org/10.1016/S1474-4422(07)70290-9.
18. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108. http://dx.doi.org/10.1097/00005650-199711000-00002.
19. Curtis L. Unit Costs of Health and Social Care 2011. Canterbury: PSSRU, University of Kent; 2011..
20. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal. London: NICE; 2008..
21. Brazier J, Ratcliffe J, Salomon J, Tsuchiya A. Measuring and Valuing Health Benefits for Economic Evaluation. Oxford: Oxford University Press; 2007..
22. Barber JA, Thompson SG. Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy 2004;9:197-204. http://dx.doi.org/10.1258/1355819042250249.
23. White I, Royston P, Wood A. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011;30:377-99. http://dx.doi.org/10.1002/sim.4067.
24. Wolinsky JS, Narayana PA, O'Connor P, Coyle PK, Ford C, Johnson K, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo controlled trial. Ann Neurol 2007;61:14-24. http://dx.doi.org/10.1002/ana.21079.
25. Sormani MP, Bruzzi P. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol 2013;12:669-76. http://dx.doi.org/10.1016/S1474-4422(13) 70103-0.
26. Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, et al. A randomized, double-blind placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011;18:1122-31. http://dx.doi.org/10.1111/j.1468-1331.2010.03328.x.
27. Zajicek J, Hobart J, Slade A, Barnes D, Mattison P, MUSEC Research Group. Multiple Sclerosis and Extract of Cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry 2012;83:1125-32. http://dx.doi.org/10.1136/jnnp-2012-302468.